Understanding serialization vs aggregation in pharma is essential for any track-and-trace program. The two are often discussed together, but they solve very different problems. Serialization assigns a unique identity to each saleable pack for verification, while aggregation links packs into cartons, cases, and pallets to enable efficient, compliant supply chain operations.
Serialization answers: “How do I uniquely identify each saleable unit so it can be verified anywhere in the supply chain?” Under modern regulations, that identification is typically printed as a machine-readable 2D DataMatrix (and sometimes a QR code for certain markets), plus human-readable text.
For example, U.S. DSCSA product identifier guidance describes a product identifier that includes the NDC + serial number + lot number + expiration date, carried in human- and machine-readable form (commonly a 2D DataMatrix for packages).
Aggregation answers: “How do I link those serialized units into the cartons, shippers, and pallets they travel in, so I can scan one code and know what’s inside?” GS1 describes aggregation as the creation of a hierarchical parent-child relationship between a containing object (parent) and the objects it contains (children).
Why the distinction matters: serialization is primarily about unique identity and verification, while aggregation is about logistics efficiency and hierarchy integrity. And when you combine both, you unlock faster receiving, shipping, returns, and better exception handling across the supply chain.
PharmaSecure’s ecosystem reflects this “serialization + aggregation + data exchange” reality; it offers serialization software (for requesting, allocating, printing, reconciling, and auditing codes) and purpose-built line hardware that can create recipe-based aggregation and parent-child relationships with minimal operational disruption.
Pharmaceutical serialization is the process of assigning a unique identifier to each pack (usually the smallest saleable unit) and encoding it in a barcode, so that individual packs can be authenticated, traced, and verified. In practice, serialization programs combine:
PharmaSecure describes its serialization solution set as compliant, customizable, and designed to minimize disruption, highlighting its psID manage suite and psID TruTrak (hardware + software) as core offerings.
The exact structure depends on the regulation and market, but most systems converge on a common set of core data elements product identifier (product code), serial number, lot/batch, and expiry.
FDA guidance explains that the product identifier on a drug package label includes NDC, serial number, lot number, and expiration date, in both human-readable and machine-readable (2D DataMatrix for packages) form.
EU Delegated Regulation (EU) 2016/161 specifies that the unique identifier consists of data elements including a product code, a serial number, a national reimbursement number or other national number (if required by the Member State), the batch number, and the expiry date.
The same regulation requires manufacturers to encode the unique identifier in a two-dimensional barcode, specifically a Data Matrix with required error detection/correction characteristics (ECC200-level), and provides expectations on structure and decoding using recognized coding schemes.
On its Global Compliance guidance, PharmaSecure gives a clear GS1-style example (commonly used across many markets):
In other words, serialization is not just “printing a barcode.” It’s printing a barcode that encodes regulated data elements in a standardized syntax, then controlling that data across a validated workflow.
psID® Manage™ supports requesting, fulfilling, allocating, printing, and reconciling codes with role-based access control, dashboards, and audit trails.
psID Imprint™ is designed to connect in real time to printers and scanning devices to reduce line setup time and protect serial number integrity.
psID® Express supports generating and downloading unique psID® codes through a secure web portal.
For the shop floor, the psID® TruTrak® Serialization Machine provides variable printing and code grading/qualification with duplicate rejection and OCR/OCV, in a GMP design with 21 CFR Part 11 compliance claims.
Serialization became mandatory because regulators needed a scalable way to prevent falsified, diverted, and illegitimate medicines from moving undetected through complex global supply chains.
The DSCSA (as part of the Drug Quality and Security Act) outlines steps to build an electronic, interoperable system to identify and trace certain prescription drugs distributed in the U.S.
A key component is the requirement for a product identifier on packages (and in certain cases), and the FDA’s product identifier guidance explains what must be encoded (NDC/serial/lot/expiration) and how it should appear.
The EU’s safety-features framework requires most prescription medicines (and certain OTCs) to carry:
A unique identifier in a 2D barcode, and
An anti-tampering device is on the outer packaging.
The European Medicines Agency summarizes the go-live milestone; as of 9 February 2019, these safety features became required for most prescription medicines in the EU.
Aggregation in pharmaceuticals is the process of linking serialized items to the containers that hold them, creating a digital packaging hierarchy.
GS1’s aggregation discussion paper defines aggregation as establishing a hierarchical, parent-child relationship between a container (parent) and one or more contained objects (children).
This is why aggregation is sometimes called:
PharmaSecure’s hardware catalog reflects these realities; it offers equipment designed not only to serialize, but also to define parent–child relationships through recipe-based aggregation, including pallet-level aggregation.
A parent-child relationship is a data association like:
Once that relationship exists, scanning the parent code can “represent” the full contents without scanning every child every time (as long as the relationship remains intact and the data is trustworthy).
GS1 explicitly frames aggregation around a containing object (parent) and contained objects (children).
PharmaSecure mirrors this in its product language. Its Serialization & Aggregation Machine is described as enabling serialization and defining a parent-child relationship, featuring recipe-based aggregation (parent-child relationship).
In practice, parent-child integrity is protected by line controls such as:
duplicate detection and rejection
scan validation (vision systems)
controlled rework flows (de-aggregation and re-aggregation)
PharmaSecure’s software suite supports operational processes like de-aggregation or re-aggregation through psID® Shipment.
A simple way to think about the packaging hierarchy is:
GS1 distinguishes between: a trade item (identified by a GTIN) and a logistic unit (identified by an SSCC).
It also notes that bundles in aggregation can optionally be uniquely identified by either an SGTIN or an SSCC, depending on the role and agreements in the supply chain.
PharmaSecure’s equipment lineup also aligns with this hierarchy:
Serialization and aggregation are complementary, but they operate at different layers of the traceability stack.
Serialization is about identity; aggregation is about relationships.
Dimension | Serialization | Aggregation |
Primary purpose | Assign a unique ID to each pack for verification and traceability | Link pack IDs into hierarchies so containers can be scanned as proxies for their contents |
What it creates | A unique identifier on a pack (2D barcode + human-readable) | Parent-child associations among packaging levels |
Where it happens | Printing + verification on packaging lines | Typically, on packaging/aggregation stations (bundle, case, pallet), using scan confirmation |
| Operational impact | Enables unit-level verification, recall targeting, and anti-counterfeit controls | Enables fast warehouse operations, shipping/receiving, and returns handling with fewer scans (when trusted) |
Regulators generally mandate serialization, while aggregation is more uneven globally.
Aggregation, by contrast, is often driven by country-specific mandates or by business needs (speed and data quality). PharmaSecure’s own country guidance examples show that some markets include explicit aggregation expectations (for example, India export requirements include “Aggregation: Yes”).
And in Russia, PharmaSecure notes that manufacturers/importers must comply with additional serialization and aggregation regulations and report aggregation activities (packing/unpacking events).
The strongest programs treat serialization and aggregation as one continuous, validated process from line to warehouse to partner data exchange.
A practical workflow (aligned to what manufacturers and CMOs implement) looks like this:
Generate serial numbers securely: PharmaSecure’s track-and-trace description explains that unique/random alphanumeric codes can be generated on a secure server and transferred to manufacturing via encrypted file transfer.
Commission and print data on packs (serialization): A line prints variable 2D codes and verifies print quality and readability (grading/qualification, OCR/OCV).
Verify and reject exceptions: Duplicate detection and rejection help maintain data integrity so that serial numbers are not accidentally reused.
Build relationships (aggregation): (a) unit → bundle (optional), (b) bundle → case, (c) case → pallet. With PharmaSecure, this mapping is explicitly supported in both hardware (recipe-based aggregation) and software.
Label tertiary packaging and logistics units: Hardware such as label applicators and pallet aggregation stations can support code generation/labeling and aggregation controls at shipping levels.
Ship and trace events through the supply chain: PharmaSecure’s Track & Trace positioning emphasizes visibility from manufacturing to final delivery with partner scanning at receipt/dispatch and analytics for diversion and recall responsiveness.
Manage exceptions: de-aggregation and re-aggregation: Real-world distribution includes repacking, partial shipments, and rework. PharmaSecure’s psID® Shipment explicitly supports de-aggregation/re-aggregation and related shipping activities.
Once you serialize and aggregate, you still need to exchange trustworthy event data across trading partners. That’s where EPCIS (Electronic Product Code Information Services) becomes essential.
GS1 describes EPCIS as a data sharing standard that provides the “what, when, where, why and how” of products and other assets, enabling interoperable information sharing across trading partners.
For DSCSA, FDA’s September 2023 interoperability guidance explicitly recommends that trading partners use the EPCIS standard to provide and maintain the data associated with transaction information and transaction statements, describing EPCIS as a global GS1 standard for capturing and sharing information as products move through the supply chain.
PharmaSecure also reinforces this standardization in its own educational content, calling EPCIS a global standard for sharing event data such as commissioning, aggregation, shipping, and receipt.
In most discussions, the most accurate answer is:
FDA’s “Enhanced Drug Distribution Security at the Package Level” guidance states that it describes system attributes necessary for secure product tracing and verification, including when the use of verification, inference, and aggregation may be appropriate.
At the same time, major distributors note that the DSCSA does not explicitly require aggregation data to be shared for each pallet, even though skipping aggregation can be a practical problem.
So, legally, aggregation is not clearly imposed as a standalone “must-do” requirement in the DSCSA text the way serialization is. Practically, it is hard to run high-volume distribution without it.
EU FMD’s safety features regulation focuses on the unique identifier and anti-tampering at the pack level and requires encoding the unique identifier into a 2D Data Matrix.
A practical clue: some solution providers note that the European Hub does not accept certain aggregation data fields, such as pallet IDs for upload, which reflects the pack-level verification focus of the EU system.
But globally, aggregation can be mandatory in other markets. For example, PharmaSecure’s Russia-focused regulatory overview highlights additional serialization and aggregation requirements and the need to report aggregation activities.
PharmaSecure’s Global Compliance guidance also shows markets where aggregation is explicitly indicated as “Yes” (e.g., India exports).
Yes. Serialization can exist without aggregation because serialization is simply the act of uniquely identifying individual packs and managing that identity through commissioning, verification, and reconciliation.
However, the operational cost of “serialization without aggregation” grows quickly:
In other words, you can serialize without aggregating, but you often end up paying for it later in labor, time, and exception handling.
When combined, serialization + aggregation create a traceability system that is both accurate at the unit level and efficient at the logistics level.
Aggregation is an efficiency multiplier because it reduces scanning intensity across high-volume flows.
GS1’s aggregation paper shows aggregation as a mechanism to infer the full packing hierarchy at shipping/receiving based on prior packing steps, following GS1 identification, capture, and sharing flows (including EPCIS aggregation events).
This is why many pharma supply chains use aggregation to support fast receiving and shipping without opening every container.
Where PharmaSecure supports these efficiencies in practice:
Operationally, this combination can improve: warehouse throughput cycle counts and inventory confidence returns processing speed (especially where saleable returns workflows exist).
While aggregation may be “optional” in some legal frameworks, combining it with serialization strengthens compliance posture and reduces risk in ways that auditors and quality teams care about.
PharmaSecure also offers supporting software components that strengthen control and auditability:
Serialization and aggregation are proven, but implementation is rarely “plug and play.” Challenges typically fall into two buckets: technical execution (line + data) and compliance/validation (quality + controls).
Most technical issues come from the fact that you’re synchronizing physical motion (fast packaging lines) with digital truth (event data that must be accurate, complete, and timely).
Common challenges include:
In regulated pharma operations, the system has to work and also has to be provably controlled. Key compliance challenges include:
Is serialization the same thing as track-and-trace?
Not exactly. Serialization is the unique identification step (assigning a unique identifier to each pack). Track-and-trace includes serialization plus capturing and analyzing events as products move. PharmaSecure’s Track & Trace positioning emphasizes end-to-end visibility and event tracing from manufacturing to delivery.
What barcode type is commonly required for pharma serialization?
In both DSCSA and EU FMD contexts, the machine-readable carrier is commonly a 2D DataMatrix. FDA’s product identifier guidance references the 2D data matrix barcode format for packages, and EU Delegated Regulation 2016/161 requires the unique identifier to be encoded in a two-dimensional barcode that is a Data Matrix with ECC200-level error correction.
What does “commissioning” mean in serialization projects?
Commissioning typically refers to the event where a serial number is assigned to a physical pack and becomes “active” in the system. This type of event is often exchanged in EPCIS flows (along with aggregation, shipping, and receiving).
Does the EU FMD require sharing EPCIS with trading partners?
EU FMD is primarily a pack verification and decommissioning system connected to repositories (as described by EMVO and the delegated regulation). It does not mandate EPCIS as DSCSA does.
What is the difference between aggregation and “inference”?
Aggregation is the creation of the parent–child hierarchy itself. Inference is using that trusted hierarchy to infer a container’s contents from scanning the parent. FDA’s enhanced security guidance explicitly discusses verification, inference, and aggregation as part of secure tracing system attributes.
Which PharmaSecure products support aggregation workflows?
On the software side, psID® Aggregate is described as assigning serial numbers to items, cases, and pallets and creating parent–child relationships for shipping and tracking. On the hardware side, PharmaSecure offers dedicated devices like the Serialization & Aggregation Machine, Bundle Scanning Machine (two-level aggregation), and Pallet Aggregation Machine.
Serialization and aggregation are related, but they are not interchangeable:
Regulators mandate serialization (DSCSA and EU FMD), and while aggregation may not be explicitly required in those two systems, it is often necessary for efficient, accurate operations, and is mandatory in several other markets.
For manufacturers and CMOs building a future-ready traceability program, the best strategy is typically to implement both together using standards-based data exchange (EPCIS for DSCSA) and validated line and enterprise controls. FDA recommends EPCIS for DSCSA interoperability, and PharmaSecure’s psID® software suite and TruTrak® hardware are positioned to support end-to-end serialization, aggregation, and track-and-trace execution.
pharmasecure seo / May 18, 2026
pharmasecure seo / April 6, 2026
pharmasecure seo / March 11, 2026
PharmaSecure is a global track-and-trace, product authentication and consumer engagement company that has helped protect billions of packages through its technology-enabled solutions. Our proven serialization capabilities have enabled large pharmaceutical companies to meet different traceability requirements.
©2025, PharmaSecure Inc. All Rights Reserved.
